Editors' note: Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In “Ordinal vs dichotomous analyses of modified Rankin Scale (mRS), 5-year outcome, and cost of stroke,” Ganesh et al. reported that the ordinal mRS correlates better with 5-year mortality/disability/cost of care than the dichotomized mRS (using either 0–1 or 0–2 to measure good outcome). To optimize the utility of future stroke trials, these findings should be considered when determining how to compare poststroke mRS scores. One problem the authors noted with dichotomization is that patients with premorbid disability are likely to automatically be characterized as having a poor outcome because they cannot get better than their premorbid status poststroke. On a related note, Bruno comments that determining the prestroke mRS is subjective and that there are no guidelines for doing so. He recommends abandoning the use of the mRS to assess prestroke functional status and, instead, using a simple dichotomization of all patients as able or unable to complete activities of daily living prestroke. Ganesh et al. agree that there is a need for prestroke disability to be uniformly designated, but they caution that their poststroke disability data suggest that an ordinal approach may be higher yield than a dichotomized one. Notably, although Ganesh et al. demonstrate that the ordinal mRS correlates with 5-year mortality/disability/cost of care, the scale has been criticized for its dependence on the ability or inability to walk resulting in the automatic classification of all patients who are unable to walk, regardless of their cognitive status, as an mRS score 4 or 5.
In “Ordinal vs dichotomous analyses of modified Rankin Scale (mRS), 5-year outcome, and cost of stroke,” Ganesh et al. reported that the ordinal mRS correlates better with 5-year mortality/disability/cost of care than the dichotomized mRS (using either 0–1 or 0–2 to measure good outcome). To optimize the utility of future stroke trials, these findings should be considered when determining how to compare poststroke mRS scores. One problem the authors noted with dichotomization is that patients with premorbid disability are likely to automatically be characterized as having a poor outcome because they cannot get better than their premorbid status poststroke. On a related note, Bruno comments that determining the prestroke mRS is subjective and that there are no guidelines for doing so. He recommends abandoning the use of the mRS to assess prestroke functional status and, instead, using a simple dichotomization of all patients as able or unable to complete activities of daily living prestroke. Ganesh et al. agree that there is a need for prestroke disability to be uniformly designated, but they caution that their poststroke disability data suggest that an ordinal approach may be higher yield than a dichotomized one. Notably, although Ganesh et al. demonstrate that the ordinal mRS correlates with 5-year mortality/disability/cost of care, the scale has been criticized for its dependence on the ability or inability to walk resulting in the automatic classification of all patients who are unable to walk, regardless of their cognitive status, as an mRS score 4 or 5.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Alert Me
Recommended articles
-
Article
Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of strokeAravind Ganesh, Ramon Luengo-Fernandez, Rose M. Wharton et al.Neurology, October 19, 2018 -
Article
Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN RegistryAdrien E. Groot, Kilian M. Treurniet, Ivo G.H. Jansen et al.Neurology, June 11, 2020 -
Article
Genome-wide association meta-analysis of functional outcome after ischemic strokeMartin Söderholm, Annie Pedersen, Erik Lorentzen et al.Neurology, February 22, 2019 -
Article
Anesthetic management during endovascular treatment of acute ischemic stroke in the MR CLEAN RegistryRobert-Jan B. Goldhoorn, Marie Louise E. Bernsen, Jeannette Hofmeijer et al.Neurology, December 05, 2019